Published in Annals of Hepatology
Introduction Determining the incidence and prevalence of PVT is difficult due to the heterogeneity of risk factors. The prevalence in cirrhotics is 1% in compensated patients and 8-25% in decompensated patients. SARS-COV2 infection presents extrapulmonary manifestations such as coagulation disorders with thrombotic angiopathy in 20-43%. In histopat...
Published in Annals of Hepatology
Introduction COVID-19 is a disease caused by the SARS-CoV-2 virus; atypical pneumonia and sepsis are the most severe manifestations of the disease. There is evidence that the virus affects the liver in different ways. The mechanism of liver damage has not yet been clearly established. Objectives To determine the frequency of alterations in the LFT ...
Published in Annals of Hepatology
Introduction and Aim Even if Sars-Cov 2 is an emergent, primarily respiratory illness, hepatic function alterations has been described by different countries. This work aims to describe the hepatic function alterations of patients with COVID-19 and their association with comorbilities and mortality. Material and Methods We conducted an observationa...
Published in Annals of Hepatology
Published in Annals of Hepatology
The epidemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has increasingly attracted worldwide concern. Liver damage or dysfunction occurred in patients with COVID-19 (mainly characterized by moderately elevated serum aspartate aminotransferase levels). However, it is not yet cl...
Published in Annals of Hepatology
Published in Annals of Hepatology
Published in Annals of Hepatology
Introduction and Objectives In many studies, varying degrees of liver damage have been reported in more than half of the COVID-19 patients. The aim of this study is to determine the effect of liver biochemical parameters abnormality on mortality in critical COVID-19 patients who have been followed in the ICU since the beginning of the pandemic proc...
Published in Annals of Hepatology
Background and Aims Clinical course of Covid-19 is not yet established in autoimmune hepatitis (AIH). About 25% of our 400 AIH-outpatients from various states in Brazil are using hydrochloroquine (HCQ) for maintenance or treatment with corticosteroids and immunosuppressants (IS). The aim is to describe the clinical features and outcomes of COVID-19...
Published in Annals of Hepatology
Introduction On January 30th of 2020, the WHO declared the COVID-19 outbreak a health emergency. In Colombia the first case was reported on March 6th of 2020. The disease has unfavorable outcomes and mortality in patients with high risk factors like solid-organ transplant recipients. In Colombia the data of the behavior disease in liver transplant ...
